



Introduction



COVID-19 is first and foremost a global health crisis and taking care of impacted people and uniting as a society to slow the spread is, and must remain, our top priority

Nonetheless, COVID-19 is also an economic crisis unlike anything seen in more than 100 years, progressing at unprecedented speed and bringing economies across the globe to a halt


The automotive industry is acutely impacted and BCG is forecasting a ~20% decline in new vehicle sales for 2020, with the potential for a global decline of more than 40% (a level not seen since the financial crisis of 2008 / 2009)

While the industry is healthier than it was a decade ago, such declines will have a tremendous impact on automotive suppliers... testing break-even points, draining cash, and in the case of some suppliers, putting their very survival at risk

Now is the time for strong, bold moves to strengthen the balance sheet and reduce costs to provide optionality through the uncertain months ahead... time is of the essence


BCG is forecasting a decline in new vehicle sales of ~20%, with worst case scenario suggesting decline of 40%+






Monthly sales (M units)





Monthly sales (M units)




Pessimistic scenario

Such declines will severely test suppliers, which as a sector, have shown little improvement in cash position since 2008



As a group, suppliers have shown little improvement in cash position relative to the financial crisis...




1. Weighted median for 30 suppliers as selected from top 50 global suppliers, excluding diversified industrials and non-publicly traded companies Note: Cash reported at year end or most recent LTM if 2019 year end not yet available; Revenue reported over fiscal year; Excludes financing/credit divisions; Cash includes Cash, Near Cash Items, and ST Investments (Money markets)


Source: S&P Capital IO, BCG Analysis


... but a spectrum exists across individuals suppliers

2019 Cash/Revenue %




2019 Cash/COGS %









^{1.} Weighted median from set of 13 leading OEMs: Tata, Ford, GM, Daimler, Tesla, Nissan, Toyota, Fiat Chrysler, VW, BMW, Peugeot, Kia, and Honda; weighted median from set of 30 global suppliers as selected from top 50 global suppliers, excluding diversified industrials and non-publicly traded companies Note: Cash reported at year end or most recent LTM if 2019 year end not yet available; Revenue reported over fiscal year; Excludes financing/credit divisions; Cash includes Cash, Near Cash Items, and Short Term Investments (money market)

Source: S&P Capital IQ, BCG Analysis

Even before COVID-19, suppliers had been under immense pressure for preceding 18–24 months




Supplier margin has been compressing...

Median¹ EBIT/sales




...leading to declining investor sentiment and valuations...

Indexed supplier¹ market returns vs. auto and S&P 500




...and downturn impacts will stretch cash positions further

Median supplier¹ cash/sales




^{1.} Weighted median from set of 30 global suppliers as selected from top 50 global suppliers, excluding diversified industrials and non-publicly traded companies; 2. As of close March 20;

^{3.} Forward P/E for select US-based auto suppliers







The response to COVID-19 requires a comprehensive approach

Shutdown management

Governmental action utilization

Portfolio

(re)priori-

tization

Supplier

steering/

commercials



changes

Implement bold strategic moves

Situation monitoring Governmental-action Consumer and **COVID-19** monitoring monitoring customer monitoring **Crisis management** Staff engagement Stakeholder engagement Takeover defense Contingency planning Tight financial steering and communication e.g., state, union, supervisory board Respond Stabilize and ramp up Leverage Immediate actions to protect Leverage crisis to build R&D Sales/Afters HR/Tech **Supply chain Procurement** Operations workforce and company lasting advantage Stabilize and run the company in the crisis Health & safety Advance structural changes Revenue Crisis Supply Safeguard Supplier Running Cash office & liquidity Strengthen business resilience chain/ working protection critical review/ operations in management inventory mode/IT and customer crisis mode projects stabilization stabilization management outreach Pursue M&A opportunities Short-term supply chain management Prepare ramp-up to win in the rebound Make bold organizational

Source: BCG analysis.

BCG'S COVID-19 AUTOMOTIVE DEMAND MODEL

Supply chain

ramp-up

(Re)conquer

market share

Workforce

(re)activation

Operations

ramp-up

Seven immediate priorities for suppliers



- 1 Launch a crisis management team, including a cash management office to shore up the balance sheet (e.g., suspend buybacks as needed, access lines of credit, freeze all non-essential spend, etc.)
- 2 Drive enterprisewide cost reductions to the core (if it doesn't hurt you are not being aggressive enough)
- 3 Conduct detailed program profitability review and look to lengthen payment terms and re-price wherever possible
- 4 Engage most critical customers, prioritize their product launches and production accordingly (make yourself essential)

- Lead by example, communicate frequently and promote 'all-hands on deck' culture (remember sacrifices when things return to normal)
- 6 Proactively reach out to investors and articulate your narrative (similarly, keep an eye toward activism, and vulnerabilities vs. peers)
- If liquidity situation allows, consider selectively going on the offensive to fill strategic gaps (refresh your M&A pipeline, monitor valuations, and move aggressively when opportunities arise)

COVID-19 Disclaimer



The situation surrounding COVID-19 is dynamic and rapidly evolving, on a daily basis. Although we have taken great care prior to producing this presentation, it represents BCG's view at a particular point in time. This presentation is not intended to: (i) constitute medical or safety advice, nor be a substitute for the same; nor (ii) be seen as a formal endorsement or recommendation of a particular response. As such you are advised to make your own assessment as to the appropriate course of action to take, using this presentation as guidance. Please carefully consider local laws and guidance in your area, particularly the most recent advice issued by your local (and national) health authorities, before making any decision.